ZetrOZ Systems developed OZ Inside™, our patented ultra-low impedance ultrasound miniaturization technology, to enable the flexible delivery of sustained acoustic medicine, a new treatment form. It effectively streamlines system architecture and optimizes electro-acoustic signal conduction to achieve peak efficiencies across the entire spectrum of ultrasound outputs.
While the use of traditional therapeutic ultrasound is typically applied in short, high intensity bursts from large systems, current research indicates that low intensity, long duration ultrasound provides an overall better and sustained solution. OZ Inside addresses this new protocol. Not restricted by acoustic power, frequency, or intensity, OZ Inside enables the delivery of sustained acoustic medicine through a wearable device designed for user flexibility.
ZetrOZ Systems currently applies this proprietary technology to its three products on the market sam® Global Health, –sam® Sport and UltrOZ™ Elite. Additional products and applications are under investigation and development through our ongoing research program.
Research & Development at ZetrOZ Systems is focused on developing a portfolio of bioelectronic devices delivering sustained acoustic medicine to treat pain and enhance healing. We concentrate on conditions insufficiently addressed by current treatments and for which large market opportunities exist. The lead product in our pipeline is directed at providing pain relief from osteoarthritis.
With funding from the NIH-National Institute of Health, ZetrOZ Systems has shown that daily sustained acoustic medicine provides symptomatic relief of knee pain related to osteoarthritis (OA), a degenerative joint disease affecting 27 million Americans. The success of this research has supported insurance coverage of sam® for arthritis pain of the knee, hip shoulder and elbow.
In our clinical pipeline we are studying the use of sustained acoustic medicine for additional applications. Research supported by the National Space Biomedical Research Institute, the United States Department of Defense, CIMIT (Center for Integration of Medicine & Innovative Technology), Connecticut Innovations and the Connecticut Department of Economic and Community Development has validated the efficacy of sam® for the treatment of upper and lower back pain, and to accelerate the healing of soft-tissue injuries.
The company’s research is frequently presented at scientific conferences and meetings in the United States and internationally. In addition, there are more than 30 publications detailing the results of research related to ultrasound therapy, and to the development of sam® Sport, UltrOZ™ Elite, and other products in development. Click here to see key presentations and publications.
ZetrOZ Systems has a portfolio of patents protecting the therapy innovation of sustained acoustic medicine. Eleven utility patents have been filed; six applications have been filed to protect the system design, and five registration and trademark applications have been filed for key branding terms, icons and logos.
International protection is in place through PCT (Patent Cooperation Treaty), with Europe, China, India and Brazil.